<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>MNOV +19.1%, BWLD +18.3%, TREE +12%, TWTR +9.4%, ECHO +7.1%, STM +6.7%, TER +5.7%, IRDM +5%, NVCR +5%, AEM +4.2%, INVA +4%, BGG +4%, DCM +3.6%, LKQ +3.3%, SXCP +3.3%, SAN +3.2%, GDI +2.9%, MAA +2.7%, ABEV +2.6%, RS +2.5%, PTC +2.4%, ABB +2.3%, VSH +2.3%, SRPT +2.2%, LVS +2%, SAVE +2%, ELY +1.9%, GG +1.7%, SU +1.7%, EQT +1.7%, MCK +1.7%, WLL +1.6%, FTI +1.6%, VALE +1.6%, F +1.5%, RTN +1.5%, VLO +1.5%, XRX +1.5%, SBGL +1.4%, CSLT +1.2%, FNF +1.1%, PX +1.1%, O +1%, CSII +1%, CX +1%, QSR +1%, AFL +0.9%, MO +0.9%<br/><b>Other news:</b><br/>VTGN +33.3% (announces FDA has authorized the Co to proceed, under its Investigational New Drug application, with its planned Phase 2 clinical study of AV-101<br/>MNOV +18.4% (announces that the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) achieved both primary endpoints)<br/>TRVN +17% (announces publication of the results of APOLLO-1 and APOLLO-2 at the 2017 Annual Meeting of the American Society of Anesthesiologists from positive Phase 3 trials )<br/>NNVC +6.3% (extended its agreement with SUNY Upstate Medical Center for further testing of its nanoviricides drug candidates against Shingles)<br/>QTNT +5.4% (indicated higher after Highbridge Capital discloses increased passive stake to 9.92%)<br/>TGTX +4.3% (announces results from the Phase 2 multicenter trial of TG-1101)<br/>PSTI +4% (received approval from Israel's Ministry of Health to initiate a Phase I trial studying the company's PLX-R18 cell therapy)<br/>AGEN +3.2% (CDC Advisory Committee on Immunization Practices voted in favor of three recommendations for the use of Shingrix containing QS-21 Stimulon for the prevention of shingles)<br/>VERU +2.8% (files for $50 mln mixed securities shelf offering)<br/>CZR +2% (LVS sympathy)<br/>TSRO +1.8% (receives FDA approval for VARUBI IV )<br/>WYNN +1.2% (LVS sympathy)<br/><b>Analyst comments:</b><br/>LEA +0.5% (upgraded to Outperform at RBC Capital Mkts)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>NOK -16.2%, UCTT -11.3%, NTRI -10.8%, TAL -10.8%, CELG -9.8%, MLNX -8.6%, ESND -8%, VAR -6.6%, OII -6.5%, ORLY -6.3%, ONCS -6.1%, JAKK -5.9%, XLNX -5.3%, UHS -5.2%, BCS -5.2%, ALKS -5%, RVLT -5%, POT -4.8%, NOW -4.5%, DLB -4%, SSNC -3.9%, BSX -3.7%, CA -3.5%, MC -3.5%, TSCO -3.3%, HLI -3.2% (also announces secondary offering of class A common stock by selling stockholders), CDE -2.9%, NTGR -2.8%, IART -2.8%, MMLP -2.7%, PKG -2.7%, AMGN -2.6%, DNKN -2.5%, KKR -2.5%, BUD -2.4%, FAF -2.4%, ABMD -2.3%, DB -2.2%, GNC -2.1%, ALLE -1.9%, MDP -1.9%, WPG -1.6%, BMY -1.6%, STO -1.4%, CMO -1%, VC -1%, RJF -0.9%, VRTX -0.9%, ABX -0.9%, PSA -0.8%, ICLR -0.8%<br/><b>Other news:</b><br/>ATOS -24.5% (proposes public offering of common stock)<br/>IDRA -21.7% (prices 33,333,334 shares at $1.50)<br/>VBIV -6% (commenced an underwritten public offering and a registered direct offering of its common shares )<br/>HCM -4.6% (prices 9,886,792 ADSs at $26.50 per share)<br/>CSX -4.5% (light volume; CSX authorized $1.5 billion in share repurchases; is postponing its scheduled October 30th Investor Conference to a later date)<br/><b>Analyst comments:</b><br/>PCRX -5.8% (downgraded to Sell from Neutral at Janney)<br/>PTCT -5.4% (downgraded to Underperform from Neutral at BofA/Merrill)<br/>TRVG -1.8% (downgraded to Underperform from Neutral at BofA/Merrill; downgraded to Neutral from Buy at Guggenheim)<br/>WWD -1.7% (downgraded to Perform from Outperform at Oppenheimer)<br/>GSK -1% (downgraded to Neutral from Buy at BofA/Merrill)<br/>LB -1% (downgraded to Neutral from Buy at Buckingham Research)<br/><br/>Briefing.com